RT @RichardPAConway: Frisell et al. Safety b/tsDMARDs from 10 years ARTIS. There is a mass of interesting data here, loo

Frisell et al. Safety b/tsDMARDs from 10 years ARTIS. There is a mass of interesting data here, look at that figure! Higher rates of discontinuation due to AEs for tofa, bari, sari, rituximab. May be explained by chanelling and residual confounding @RheumNow #EULAR2022 POS0637 https://t.co/KrspU6c9Cs